Nanodrug Delivery Systems for Lower Respiratory Infections: Pulmonary Targeting, Anti-Infective Applications, and Translational Challenges Authors: Wen-Bin Zhu, Ting Liu, Guang-Liang Cheng, Kai-Qian Xu, Jun-Mei Fang, Ying Ma, Jin-Xia Lu, Yi Xue, Ling-Ling Xu Published: 2026 ABSTRACT AbstractLower respiratory infections (LRIs) remain a leading cause of global morbidity and mortality, particularly among vulnerable populations such as children and the elderly. Although conventional antimicrobial therapies remain central to clinical management, their efficacy is often limited by poor pulmonary bioavailability, systemic toxicity, inadequate penetration of mucus or biofilms, and the rapid emergence of drug-resistant pathogens. Nanodrug delivery systems (NDDS) provide a promising strategy to address these limitations by improving pulmonary deposition, protecting labile therapeutics, enabling controlled release, and supporting disease-site targeting. In this review, we systematically summarize recent advances in NDDS for LRIs, with emphasis on the design principles and functional characteristics of lipid-based, polymeric, inorganic, and hybrid nanocarriers. We further connect these platforms with disease-specific therapeutic challenges in bacterial pneumonia, tuberculosis, viral infections, and fungal pneumonia, highlighting how carrier composition, surface engineering, and release behavior can be adapted to mucus barriers, biofilms, intracellular pathogen niches, and inflammatory microenvironments. Importantly, we discuss emerging trends, including bioinspired nanocarriers, stimuli-responsive systems, and multifunctional theranostic platforms, while also evaluating key translational barriers such as biosafety, immunogenicity, reproducible manufacturing, and regulatory standardization.Keywords: lower respiratory infections, nanodrug delivery systems, drug targeting, anti-infective Introduction Lower respiratory infections (LRIs), defined as infections affecting the anatomical structures below the larynx—including bronchitis, bronchiolitis, and pneumonia—represent a major global public health challenge, imposing a substantial burden on morbidity and mortality worldwide.1,2 According to the World Health Organization, LRIs rank among the leading causes of death globally,2 disproportionately affecting vulnerable populations such as young children, the elderly, and immunocompromised individuals. Notably, LRIs remain a principal cause of mortality in children under five years of age,3 with a particularly high disease burden in low- and middle-income countries, where limited healthcare resources further exacerbate outcomes.4,5 The etiology of LRIs is heterogeneous, encompassing bacterial, viral, and fungal pathogens.6 Current therapeutic strategies are largely pathogen-directed, relying on antibiotics, antiviral agents, or antifungal drugs depending on the underlying cause. In clinical practice, empirical administration of systemic antimicrobial agents—via oral or parenteral routes—remains the standard of care.7 However, the effectiveness of these conventional pharmacological approaches is frequently constrained by several critical limitations, including insufficient drug penetration into pulmonary tissues, low bioavailability at the site of infection, and systemic adverse effects.8,9 Moreover, the inherently low accumulation of systemically administered drugs within the lungs often necessitates high-dose regimens, thereby increasing the risk of off-target toxicity, such as hepatotoxicity and nephrotoxicity.10–12 These challenges are further compounded by the rapid emergence of antimicrobial resistance and the continuous evolution of novel respiratory pathogens, underscoring an urgent need for more effective and targeted therapeutic strategies.13,14 Recent advances in nanotechnology have opened new avenues for the precise management of LRIs.15,16 Nanodrug delivery systems (NDDS), which can be administered via inhalation or systemic routes, exhibit unique physicochemical properties that enable enhanced pulmonary targeting, improved drug stability, and controlled release profiles.17–19 Importantly, NDDS can overcome key biological barriers in the respiratory tract—including mucus layers, biofilms, and intracellular pathogen niches—thereby facilitating more efficient drug delivery to infected sites. In addition, the structural tunability of nanocarriers allows for rational design tailored to specific disease contexts, optimizing pharmacokinetics and therapeutic outcomes. A growing body of evidence has demonstrated the potential of diverse NDDS platforms—such as lipid-based nanoparticles, polymeric nanoparticles, solid lipid nanoparticles, and inorganic nanomaterials—in improving drug delivery efficiency and therapeutic efficacy in LRIs.20 To facilitate conceptual understanding, Figure 1 summarizes the major classes of nanomedicine platforms and their representative applications across bacterial, viral, and fungal respiratory infections, highlighting the relationships between nanocarrier design and disease-specific therapeutic strategies. Schematic illustration of nanodrug delivery systems for lower respiratory infections. Figure was generated with AI assistance and subsequently reviewed and edited by the authors for scientific accuracy and clarity. These systems have shown promising results in both in vitro and preclinical models, highlighting their capacity to enhance antimicrobial activity while reducing systemic toxicity. However, the significance of NDDS for LRIs cannot be fully captured by cataloguing individual nanocarrier types or isolated disease applications alone. Recent reviews have provided valuable perspectives on inhaled nanoparticulate systems, pulmonary barrier penetration, targeted pulmonary delivery, and clinical translation of inhalable nanomedicines;21,22 nevertheless, an integrated infection-oriented framework remains needed to explain how carrier composition, surface properties, release behavior, and pulmonary deposition should be matched with pathogen- and microenvironment-specific barriers.23,24 Therefore, this review aims to provide a comprehensive and systematic overview of nanodrug delivery systems for LRIs, emphasizing (1) the classification and design principles of major nanocarriers, (2) their functional advantages in improving pulmonary drug delivery and therapeutic efficacy, and (3) their applications across different respiratory infections, including bacterial pneumonia, tuberculosis, viral infections, and fungal pneumonia. By linking nanocarrier design to disease-specific therapeutic needs, biological barriers, and translational constraints, this work seeks to provide a more unified framework for the development of next-generation precision anti-infective strategies. Development and Comparison of Various Nano-Drug Delivery Systems Nanomedicine has emerged as a transformative paradigm in drug delivery, primarily owing to the unique physicochemical properties conferred by nanoscale dimensions.25 At this scale, nanocarriers can interact more efficiently with biological systems, thereby enhancing drug bioavailability, improving pharmacokinetics, and reducing off-target effects.26–28 These advantages are particularly relevant for complex diseases such as cancer and infectious disorders, where conventional formulations often fail to achieve sufficient therapeutic efficacy.29 From a structural and functional perspective, nanocarriers can be broadly categorized into organic and inorganic systems (Table 1). Organic nanocarriers—including liposomes, polymeric nanoparticles, and micelles—are predominantly composed of biocompatible and biodegradable materials, making them well-suited for clinical translation. Their primary advantages lie in their ability to enhance drug solubility, improve stability, and enable controlled release profiles.30,31 In contrast, inorganic nanocarriers, such as gold nanoparticles and silica-based systems, offer distinct physicochemical properties, including tunable optical, magnetic, and electronic characteristics, which can be leveraged for imaging-guided therapy and theranostic applications.32,33 Importantly, the selection of nanocarrier type should not be viewed merely as a material choice, but rather as a strategic decision driven by specific therapeutic requirements. Organic systems are generally favored for their superior biosafety and degradability, whereas inorganic systems provide additional functionalities but may raise concerns regarding long-term biocompatibility. Consequently, hybrid nanocarriers that integrate both organic and inorganic components have attracted increasing attention, as they combine the advantages of each platform while mitigating their individual limitations30. In the context of LRIs, these categories should also be interpreted through an infection-oriented lens, because the same carrier may perform differently depending on mucus composition, pathogen localization, inflammatory status, and the need for local versus systemic exposure. Table 1Advantages and Disadvantages of Different Types of Nano-Delivery MaterialsTypeRepresentative MaterialsAdvantagesDisadvantagesPrimary ApplicationsRefLiposomesPhospholipids, CholesterolHigh biocompatibility, Load both hydrophilic/hydrophobic drugs, Ease of preparation and modificationPotential drug leakage, Relatively poor stabilityAntibiotic delivery, Antifungal therapy, Vaccines[34]Polymeric nanoparticlesPLGA, ChitosanExcellent sustained release, High stability, BiodegradableCostly, Poor Aerosolization Efficiency, safety concernsLong-term anti-TB therapy, Gene delivery, Mucosal immunity[35]Inorganic nanoparticlesMesoporous Silica, GoldVery high drug loading, Multifunctional (magnetic, optical), High stabilityPoor biodegradability, Long-term toxicity uncertainTheranostics, Photothermal/ photodynamic therapy[36]DendrimersPAMAMPrecise structure, High loading efficiency, Easily functionalizedComplex synthesis, Potential cytotoxicityNucleic acid delivery, Immunomodulation[37]Lipid-Polymer HybridsPLGA-LipidCombine advantages of liposomes and polymers, High stability and loadingMore complex fabrication processVersatile, for various drug types[38] Advantages and Disadvantages of Different Types of Nano-Delivery Materials Another critical aspect of nanocarrier design is their responsiveness to pathological microenvironments. Through rational engineering, nanocarriers can be endowed with stimuli-responsive properties—such as sensitivity to pH, redox conditions, or enzymatic activity—enabling site-specific drug release and improving therapeutic precision. While these strategies have been extensively explored in oncology, their application in infectious diseases, particularly lower respiratory infections, remains comparatively underdeveloped and warrants further investigation. Overall, current nanodrug delivery systems have demonstrated considerable potential in improving drug delivery performance. However, each platform presents inherent trade-offs in terms of biocompatibility, drug loading capacity, stability, and functional complexity. A systematic understanding of these differences is therefore essential for guiding the rational design and clinical translation of nanomedicine-based therapies. Lipid-Based Nanoparticles Lipid-based nanoparticles have emerged as one of the most extensively investigated and clinically translatable nanodrug delivery platforms for lower respiratory infections, owing to their excellent biocompatibility, structural versatility, and ability to encapsulate a broad range of therapeutic agents.39,40 Among them, liposomes represent the most classical and well-established lipid nanocarriers. They are spherical vesicular systems composed of one or more phospholipid bilayers that self-assemble in aqueous environments, forming structures capable of encapsulating both hydrophilic and hydrophobic drugs.41 Hydrophilic molecules are entrapped within the aqueous core, whereas hydrophobic compounds are incorporated into the lipid bilayer, enabling dual-loading capability and improving formulation flexibility. From a translational perspective, liposomes have demonstrated robust potential in pulmonary infection therapy.42 A representative example is liposomal amphotericin B for invasive fungal pneumonia.43,44 Compared with free amphotericin B, which is limited by dose-dependent nephrotoxicity and systemic toxicity, liposomal encapsulation significantly improves its therapeutic index through reduced off-target exposure and altered biodistribution. This improvement is associated with decreased nonspecific membrane interaction and enhanced drug protection against premature degradation. In pulmonary environments, physicochemical modulation of liposomes, including size and lipid composition, further facilitates uptake by alveolar macrophages, thereby enhancing local drug accumulation at infection sites. Nanoliposomes, defined as nanoscale liposomes with engineered surface properties, represent an evolution of conventional liposomal systems.45–47 Among surface modification strategies, polyethylene glycol (PEG) functionalization is the most widely used approach, generating “stealth liposomes” that reduce recognition by the mononuclear phagocyte system and prolong systemic circulation. In pulmonary delivery, reduced clearance by alveolar macrophages is a key determinant of therapeutic efficiency. PEGylation therefore contributes to prolonged respiratory retention and increased probability of reaching infected regions.48 In addition, PEG chains can modulate interactions with airway mucus, enhancing nanoparticle retention within the respiratory tract. This dual effect of immune evasion and mucosal adhesion supports sustained drug release and improved local exposure. However, PEGylation also introduces a functional trade-off, as excessive steric shielding may impair cellular uptake efficiency. In addition to liposomal systems, solid lipid nanoparticles (SLNs) have gained increasing attention as an alternative lipid-based nanocarrier platform. SLNs are composed of physiological lipids that remain solid at both room and physiological temperatures, forming a stable matrix for drug incorporation. Compared with conventional emulsions, SLNs offer improved physical stability, reduced drug leakage, and controlled release characteristics.49,50 The solid lipid core provides enhanced protection of encapsulated drugs and enables sustained release, which is particularly relevant for persistent pulmonary infections. Furthermore, SLNs exhibit favorable biocompatibility, low toxicity, and industrial scalability, supporting their translational potential.51 In pulmonary applications, their deposition efficiency can be modulated through particle engineering, enabling improved drug localization in the lower respiratory tract. Despite these advantages, SLNs remain constrained by limited drug-loading capacity and potential lipid polymorphism during storage, which may compromise long-term stability and reproducibility. Polymeric Nanoparticles Polymeric nanoparticles offer a versatile platform for drug delivery in lower respiratory infections, owing to their tunable physicochemical properties and capacity for controlled drug release. Importantly, their performance is not solely determined by material composition, but also by how effectively they interact with airway mucus barriers and target cells within the infected microenvironment. Natural polymers—including chitosan and alginate—have attracted considerable attention due to their favorable biocompatibility, biodegradability, and functional adaptability.52 Chitosan, a cationic polysaccharide derived from chitin, exhibits strong mucoadhesive properties through the electrostatic interactions with negatively charged mucus components and epithelial surfaces.53,54 This characteristic can prolong drug retention in the respiratory tract and enhance local therapeutic efficacy. However, increasing evidence suggests that excessive mucoadhesion may limit nanoparticle diffusion through dense mucus layers, indicating that a balance between adhesion and penetration is critical for optimal delivery performance. Alginate, an anionic polysaccharide, can form hydrogels in the presence of divalent cations, enabling efficient drug encapsulation and protection against degradation.55,56 Such systems are particularly advantageous for stabilizing sensitive therapeutics. Nevertheless, their relatively weak interaction with cellular membranes may restrict intracellular delivery efficiency, which has prompted the development of modified or composite systems to improve cellular uptake.57 Hyaluronic acid (HA), a naturally occurring glycosaminoglycan abundant in the extracellular matrix, provides an additional targeting strategy. HA-based nanoparticles can interact with receptors such as CD44 expressed on activated immune cells, thereby facilitating site-specific drug delivery.58,59 While this receptor-mediated targeting has been extensively explored in oncology, its application in respiratory infections remains less well defined, particularly in the context of complex inflammatory microenvironments. Synthetic polymers, including poly(lactic-co-glycolic acid) (PLGA) and polyethylenimine (PEI), offer greater flexibility in controlling nanoparticle structure and function. PLGA, an FDA-approved biodegradable copolymer, enables tunable drug release through modulation of its monomer ratio and particle architecture.60,61 This property supports sustained therapeutic exposure in the respiratory tract. However, unmodified PLGA nanoparticles often exhibit limited mucus penetration and cellular internalization, highlighting the need for surface engineering strategies to improve delivery efficiency. PEI is widely utilized for nucleic acid delivery due to its strong cationic charge and high nucleic acid-binding capacity.62 It can effectively condense genetic material into nanoparticles, protecting it from degradation and facilitating cellular uptake.63,64 Despite these advantages, its high charge density is associated with cytotoxicity and potential inflammatory responses, which remain major barriers to clinical translation.65 Consequently, recent efforts have focused on developing modified PEI derivatives or hybrid systems that retain transfection efficiency while minimizing toxicity. In summary, polymeric nanoparticles provide a flexible and powerful platform for respiratory drug delivery, yet their effectiveness depends on achieving a balance between mucus interaction, cellular uptake, and biocompatibility. Current studies tend to emphasize individual material advantages, while integrated design strategies remain insufficient. Future research should therefore prioritize multifunctional and hybrid systems tailored to the pathological features of lower respiratory infections to enhance clinical applicability. Inorganic and Emerging Nano-Systems Inorganic nanoparticles and emerging nano-systems have attracted increasing attention for the treatment of lower respiratory infections due to their unique physicochemical properties, including tunable structures, multifunctionality, and responsiveness to external or internal stimuli. Compared with polymeric systems, these platforms offer additional advantages in imaging integration, stimulus-responsive release, and high drug-loading capacity, although their clinical translation remains constrained by safety concerns. Mesoporous silica nanoparticles (MSNs), gold nanoparticles, and iron oxide nanoparticles represent the most extensively studied inorganic nanocarriers. Among these, MSNs are particularly notable for their highly ordered porous structures and large surface areas, which enable efficient drug loading and flexible surface functionalization.66 Their pore structures can be engineered to respond to environmental stimuli such as pH, allowing for site-specific drug release in the acidic microenvironment associated with infected lung tissues.67 This stimulus-responsive behavior provides a clear advantage for improving therapeutic precision; however, the heterogeneity of infection sites and local pH conditions may limit the consistency of such strategies in vivo, an aspect that remains insufficiently addressed in current studies. Superparamagnetic iron oxide nanoparticles enable magnetically guided targeting under an external magnetic field, offering a strategy to enhance drug accumulation at pulmonary lesions. While this approach is conceptually attractive, its practical application in deep lung regions is still challenged by the limited penetration of external magnetic fields and the complexity of respiratory dynamics. More broadly, despite the functional versatility of inorganic nanoparticles, their long-term biocompatibility, degradation pathways, and potential accumulation in organs remain major barriers to clinical translation.68 Beyond classical inorganic systems, several emerging nano-platforms further expand the design space for respiratory drug delivery. Dendrimers, characterized by their highly branched and monodisperse architecture, allow precise control over size and surface functionality. Their well-defined structure enables the incorporation of targeting ligands, drugs, or imaging agents, making them versatile delivery systems.69 Additionally, dendrimers can exhibit intrinsic antimicrobial activity depending on their surface chemistry.70 However, their relatively complex synthesis and potential cytotoxicity at higher generations necessitate careful structural optimization to balance efficacy and safety. Metal–organic frameworks (MOFs) have also emerged as promising nanocarriers due to their exceptionally high surface area and tunable pore architecture.71 These features support high drug-loading capacity and controlled release behavior, making them suitable for delivering antibiotics, antivirals, or antifungal agents to infected lung tissues.59,72,73 Importantly, recent advances in MOF design have focused on improving biodegradability and biocompatibility, which are critical for pulmonary applications. Nevertheless, their stability under physiological conditions and potential metal ion-related toxicity remain important concerns that require further investigation. Carbon-based nanomaterials, including carbon nanotubes and graphene oxide, offer unique advantages such as high surface area and efficient cellular penetration.74 These materials can be functionalized to enable intracellular drug delivery and co-loading of therapeutic and diagnostic agents. In particular, graphene oxide has demonstrated potential as a multifunctional platform integrating drug delivery with pathogen detection.61 However, similar to other inorganic systems, issues related to long-term toxicity, inflammatory responses, and clearance pathways continue to limit their translational potential. In summary, inorganic and emerging nano-systems provide unique opportunities for enhancing respiratory drug delivery through stimulus responsiveness, high loading capacity, and multifunctional integration. However, current research remains largely focused on material properties, with insufficient attention to disease-specific physiological barriers and safety profiles. Future efforts should prioritize rational design strategies that integrate functionality with biocompatibility, as well as systematic evaluation of in vivo behavior to facilitate clinical translation. Application of Nano-Drug Delivery Systems in Various Respiratory Infections Bacterial Pneumonia Bacterial infections remain the predominant cause of lower respiratory tract diseases, with major pathogens including Streptococcus pneumoniae, Pseudomonas aeruginosa, Staphylococcus aureus, Haemophilus influenzae, and Mycobacterium tuberculosis. Among these, multidrug-resistant (MDR) strains—particularly P. aeruginosa and methicillin-resistant S. aureus (MRSA)—represent a rapidly escalating clinical challenge due to limited therapeutic options and high mortality rates.75 Nano-drug delivery systems (NDDS) offer significant potential to overcome these barriers by enhancing pulmonary drug deposition, improving penetration through bacterial biofilms, and facilitating intracellular drug delivery, thereby targeting key mechanisms underlying bacterial persistence and resistance.76 Recent advances in NDDS for bacterial pneumonia have shifted from conventional antibiotic delivery toward multifunctional and mechanism-oriented strategies. For example, nanoparticle-based vaccine and immunomodulatory platforms have demonstrated the capacity to enhance host immune responses against respiratory pathogens, including the induction of Th17 immunity and activation of innate immune signaling pathways.77,78 This indicates that NDDS can function beyond passive carriers, acting as active regulators of host–pathogen interactions; however, the balance between therapeutic immune activation and excessive inflammation remains a critical issue that requires further investigation. In parallel, bioinspired and biomimetic nanoplatforms have emerged as effective approaches to overcome key pulmonary barriers. Systems incorporating cell membrane coatings or engineered motility exhibit enhanced mucus penetration, immune evasion, and targeted delivery to infection sites.79,80 These properties are particularly advantageous in biofilm-associated infections, where conventional antibiotics often fail due to limited penetration. Nevertheless, the increasing structural complexity of such systems raises concerns regarding scalability, reproducibility, and regulatory approval, which may limit their translational potential. Another important direction is the development of combination and synergistic nanotherapies, particularly for combating biofilm-mediated resistance. Co-delivery systems integrating antibiotics with metallic nanoparticles or other antimicrobial agents have demonstrated enhanced antibacterial activity and improved disruption of biofilm architecture.66 As illustrated in Figure 2,66 representative polyelectrolyte nanocomplex systems exhibit well-controlled physicochemical characteristics—including particle size, surface charge, and encapsulation efficiency—which directly influence their distribution within biofilms. More importantly, these systems translate nanoscale design into tangible therapeutic benefits, including reduced bacterial burden, improved lung histopathology, and significantly enhanced survival in infected models. This highlights that rational engineering of nanoparticle properties is a key determinant of in vivo efficacy rather than merely a formulation parameter. Advanced nanoplatforms have also been developed to achieve targeted and responsive drug delivery within the infected lung microenvironment. Peptide-based self-assembling nanoparticles and inflammation-responsive systems enable selective accumulation in diseased tissues and on-demand drug release.81,82 Notably, some platforms integrate both antibacterial and immunomodulatory functions, addressing not only pathogen eradication but also dysregulated host inflammation. As shown in Figure 3,82 such systems combine molecular-level design with self-assembly to form functional nanoparticles capable of simultaneously disrupting bacterial membranes and promoting macrophage polarization toward a reparative phenotype. The associated improvements in lung pathology and survival further emphasize the therapeutic value of this dual-functional strategy, particularly in severe pneumonia where inflammatory damage is a major contributor to disease progression. Representative polyelectrolyte nanocomplex systems for bacterial pneumonia. (A) Representative three-dimensional (3D) projections of confocal fluorescence microscopy images of PA14 biofilms treated with Tob, AgTob-NC 2a, or AgTob-NC 2b. Scale bars, 25 μm. Images were obtained at ×40 magnification. (B) Scanning electron microscopy (SEM) image of AgTob-NCs. Scale bars, 2 μm. (C) Tob-NC design parameters with Tob:DS-dependent trends for NC size and Tob ee%; AgTob-NC design parameters for TMC-dependent NC size and charge. (D) Kaplan-Meier curve revealed improved survival outcomes in NC-treated mice. (E) AgTob-NCs effectively reduced bacterial infection in mice (*P < 0.05; **P < 0.01). (F) Representative images of hematoxylin and eosin–stained lung sections for PBS-, Tob-, and NC-treated mice. Scale bars, 100 μm. Reproduced/adapted under CC BY 4.0. Self-assembling peptide nanoparticles for anti-inflammatory programming and antibacterial treatment in acute lung injury. (A) The molecular design and the discovery of a biocompatible SPRAY with dual M2 macrophage polarization and antibacterial activity. (B) The N-terminal modification renders self-assembly to induce nanoparticle formation and cytoplasmic release of functional anti-inflammatory sequence. (C) Representative SEM images of peptide-treated MRE. The membrane disruption was indicated by white arrow; the debris of MRE is indicated by black arrow. Scale bar, 400 nm. (D) Representative H&E staining images of lung (0.5× field for wide view, scale bar, 2.5 mm; 20× field for enlarged region, scale bar, 100 μm). (E). The survival rate. Reproduced/adapted under CC BY 4.0. A variety of drug-loaded nanoparticle formulations have demonstrated promising therapeutic potential in bacterial pneumonia by improving drug delivery efficiency, enhancing biofilm disruption, and modulating inflammatory responses. Rather than isolated advances, these systems can be categorized according to their primary functional strategies. First, several studies focus on improving pulmonary retention and mucus interaction to enhance local drug availability. Casein–chitosan nanoparticles and mucoadhesive chitosan-based systems prolong lung residence time while reducing bacterial burden and inflammatory cytokine levels.83,84 Similarly, nanoparticle-in-liposome hybrids further enhance lung deposition and mucus penetration with low cytotoxicity. These findings indicate that optimizing nanoparticle–mucus interactions is a key determinant of therapeutic efficacy in pulmonary infections. Second, biofilm-targeting and antibacterial enhancement strategies have been widely investigated. Amphiphilic nanoparticles and lipid-based carriers effectively disrupt biofilm structures and eliminate both planktonic and sessile bacteria at lower doses than conventional antibiotics.85 Natural compound-loaded systems, such as baicalein nanoparticles, further enhance antibacterial activity via membrane disruption and inhibition of biofilm formation.70 These results underscore the importance of addressing biofilm-associated resistance, a major limitation of current antibiotic therapy. Third, intracellular delivery and infection clearance strategies have gained increasing attention. PLGA-based nanoparticles and nanoemulsions facilitate macrophage uptake and improve intracellular antibiotic delivery, leading to more effective clearance of intracellular pathogens.86,87 Notably, these systems demonstrate both potent in vitro antibacterial activity and improved survival in vivo, suggesting their potential for persistent and recurrent infections. These systems improve drug solubility, prolong pulmonary retention, and enhance intracellular delivery, thereby contributing to improved antibacterial efficacy. However, many of these studies remain at the proof-of-concept stage, and their relative advantages over existing therapies are not always systematically evaluated. This underscores a broader limitation in the field, where comparative and translational studies are still lacking. In summary, NDDS provide multiple complementary strategies for improving the treatment of bacterial pneumonia, including enhanced drug delivery, biofilm penetration, immune modulation, and targeted therapy. However, current research remains largely driven by individual system design rather than disease-oriented integration, with limited standardization across studies. The absence of clinically relevant evaluation frameworks further hinders translation. Future efforts should therefore focus on mechanism-driven design, comparative validation, and scalability to fully realize the clinical potential of NDDS in combating MDR respiratory infections. Tuberculosis Tuberculosis (TB) remains a major global health challenge, largely driven by drug-resistant strains and the limitations of prolonged multidrug regimens.88 Standard treatment with isoniazid, rifampicin, pyrazinamide, and ethambutol requires 6–9 months of therapy, often resulting in poor compliance and treatment failure. The emergence of multidrug-resistant and extensively drug-resistant strains further complicates disease control.89 Resistance is mainly attributed to genetic mutations, inadequate drug exposure, and suboptimal pharmacokinetics, underscoring the urgent need for strategies that enhance drug delivery while improving therapeutic precision. Nanotechnology-based drug delivery systems have therefore been extensively investigated to overcome these limitations.90 Among polymeric systems, inhalable rifampicin-loaded Soluplus micelles significantly improve solubility and pulmonary deposition, achieving enhanced anti-mycobacterial efficacy.91 More advanced long-acting formulations have also been developed. As illustrated in Figure 4,92 rifabutin-loaded PLGA-based implants maintain sustained plasma concentrations above the minimum inhibitory concentration for over 16 weeks, resulting in reduced bacterial burden in the lung and spleen and prevention of granuloma formation after Mtb exposure. These findings highlight the potential of controlled-release systems to achieve both prophylactic and therapeutic effects in TB management. Inhalable PLGA-based nanoparticles further improve lung targeting, as demonstrated by lactose-coated NAC-loaded systems with sustained release and significantly enhanced antimycobacterial activity.93 In addition, immunomodulatory nanoparticles that activate autophagy pathways in macrophages have been shown to reduce pulmonary bacterial burden without systemic toxicity.75 Collectively, these studies indicate that polymeric nanocarriers can simultaneously improve pharmacokinetics and host-directed immune responses. Beyond polymeric systems, lipid-based nanocarriers have been widely explored for co-delivery of first-line anti-TB drugs. Liposomal formulations of isoniazid, rifampicin, and pyrazinamide enable synchronized drug delivery to infection sites, improving therapeutic consistency and stability.94 Mannose-functionalized solid lipid nanoparticles further enhance macrophage targeting and intracellular drug accumulation, leading to improved antibacterial efficacy.95 In parallel, amorphous drug nanoparticles have been developed to address solubility limitations of poorly water-soluble agents such as bedaquiline, significantly improving dissolution and in vivo efficacy.96 Long-acting rifabutin formulation for tuberculosis-related pulmonary infection models. (A) Formalin-fixed whole lung lobes of mice treated with placebo or Long-acting rifabutin (LA-RFB) prior to Mtb exposure, and microphotographs of the implant surface and the internal structure without and without additives. (B) Quantitative SEM analysis of implant surface images for changes in porous area (*P = 0.032, **P = 0.024, ***P = 0.0136, **** P = 0.0001, &P = 0.056, $P = 0.0242, #P = 0.0021) and pore size (#P = 0.0027, &P = 0.001) over time. (C) RFB plasma concentration after a single subcutaneous injection into BALB/c mice of LA-RFB ISFI formulations with RFB9, RFB11, RFB13 and without RFB9KH, RFB11KH, RFB13KH. (D) Representative H&E staining of lung sections shows pathological changes in pre-exposure mice treated with placebo or RFB14KH. Scale bars in H&E images are 300 μm in low magnification images and 50 μm in higher magnification images. Arrows in panels indicate lesions caused by Mtb. (E) Bacterial burden in RFB14KH treated mice 7 days and 4 weeks post Mtb exposure. i Bacterial burden in mice 7 days post Mtb exposure (n = 6). ii Bacterial burden 4 weeks post Mtb exposure, mean +/− SEM are shown (n = 6 per group, &P = 0.0022, Mann–Whitney U-test). Dotted lines in panels indicate the limit of detection. Reproduced/adapted under CC BY 4.0. More recently, targeted and multifunctional nanoplatforms have expanded the scope of TB nanotherapy. Macrophage membrane-coated nanoparticles enable dual imaging and photothermal bacterial eradication, reducing lung pathology and inflammation.97 Gene-silencing nanocarriers targeting M2 macrophages further suppress granuloma progression by modulating host immune microenvironments.98 In addition, intranasal nanovaccines based on cGAMP-adjuvanted liposomes induce strong Th1/Th17 responses and protective immunity comparable to BCG.99 Furthermore, inhalable mesoporous silica-based porous particles provide a dual micro–nano drug delivery system that enhances pulmonary dissolution and achieves simultaneous extracellular and intracellular bacterial targeting.100 Notably, this design concept bridges traditional drug delivery and nano-enabled pulmonary targeting strategies, representing a more integrated therapeutic direction. Viral Infections Viral respiratory infections, particularly COVID-19 caused by SARS-CoV-2, have highlighted the limitations of conventional antiviral and immunomodulatory therapies in terms of delivery efficiency, systemic toxicity, and variant-driven resistance. Although agents such as remdesivir provide clinical benefit in hospitalized patients, their intravenous administration restricts early outpatient use,101 while oral antivirals such as nirmatrelvir/ritonavir offer improved accessibility but remain limited by resistance development and patient-specific variability.102 In contrast, repurposed drugs such as hydroxychloroquine and lopinavir/ritonavir have failed to demonstrate consistent clinical efficacy, emphasizing the difficulty of identifying broadly effective monotherapies.103,104 These challenges collectively suggest that antiviral strategies should shift from single-drug intervention toward multi-modal delivery and host–virus interaction modulation.105 Nanotechnology-based platforms have therefore emerged as a key strategy to improve antiviral drug delivery and enable lung-targeted therapy. Polymeric nanoparticles, for instance, can significantly enhance the solubility, stability, and cellular uptake of remdesivir.106,107 In vitro studies using SARS-CoV-2-infected lung epithelial cells demonstrated that nanoparticle-encapsulated remdesivir achieves higher intracellular drug concentrations and more effective suppression of viral replication compared with free drug,106 highlighting the importance of intracellular delivery efficiency as a limiting factor in antiviral therapy. In addition, beyond antiviral drugs, nanoparticle-based immunomodulatory systems have gained increasing attention for regulating host inflammatory responses. Inhalable neutrophil-derived nanovesicles loaded with dexamethasone (iSEND) preferentially accumulate in inflamed lungs, achieving effective cytokine neutralization and macrophage modulation, while requiring significantly lower doses than systemic administration.108 Similarly, lipid-encapsulated gold nanoparticle nanoemulsions demonstrate dual antiviral and anti-inflammatory activity by suppressing IL-6 and NF-κB signaling and reducing lung injury in SARS-CoV-2 models.109 Notably, as illustrated in Figure 5,109 the Korean ginseng seed oil-based nanoemulsion system further integrates antiviral and anti-inflammatory effects by downregulating ACE2 and inflammatory signaling pathways while simultaneously reducing viral load and lung pathology in vivo, providing a representative example of multifunctional nanoplatforms that combine drug delivery with host response regulation. Nucleic acid-based nanodelivery systems have further expanded the antiviral toolbox. siRNA-loaded lipid nanoparticles targeting viral genes can effectively reduce pulmonary viral load and inflammation following intranasal administration.110 In parallel, lipid nanoparticle (LNP)-based mRNA vaccines have demonstrated robust immunogenicity and clinical protection by enabling efficient intracellular mRNA delivery and antigen expression.111,112 These systems highlight that nanoparticle engineering is not only a delivery strategy but also a platform technology enabling programmable immune activation. Korean ginseng nanoemulsion in a SARS-CoV-2-related pulmonary infection model. (A) Physicochemical characterization of Korean ginseng nanoemulsion (KGS-NE). TEM image highlighting KGR-GNP (red arrow) encapsulated by KGS-NE (Orange arrow). (B) KGS-NE treatment suppressed ACE2, Iba-1, CD68, IL-6, p-NF-κB/NF-κB through protein expression. (C) Effect of KGS-NE on lung morphological changes in Syrian hamsters infected with SARS-CoV-2. (D) Histopathology (H&E) staining performed to assess lung pathology in Syrian hamsters infected with SARS-CoV-2. Red arrows indicate pathological lung tissue inflammation. (E) Body weight and the viral load changes after infecting SARS-CoV-2 and KGS-NE administration. RT-PCR was used to estimate the viral load of RdRp and E gene (*P < 0.05). Reproduced/adapted under CC BY 4.0. Recent advances have further extended nanotherapeutic strategies toward multifunctional and targeted systems. PLGA-based nanoparticles encapsulating antiviral agents improve pulmonary delivery and significantly reduce viral replication and inflammation.113 Lung-targeted siRNA-loaded lipid nanoparticles targeting host factors such as USP33 further demonstrate that host-directed nanotherapy can effectively suppress viral replication.114 In addition, nanoparticle-based vaccine platforms displaying multivalent antigens provide cross-protective immunity against emerging coronavirus variants.115 Aerosolizable nanoliposomes and endolysosome-targeted systems further enhance pulmonary delivery and intracellular antiviral activity.116,117 Collectively, these systems suggest that precision targeting of both viral components and host pathways is becoming a central direction in antiviral nanomedicine. Beyond SARS-CoV-2, similar nanotechnology strategies have been applied to other respiratory viruses. Influenza virus remains a major global health burden, and nanodelivery systems have been developed to improve antiviral pharmacokinetics and vaccine efficacy.118 A general nucleotide-loaded nanoplatform enables pH-responsive release and significantly improves antiviral efficacy compared with conventional small-molecule therapy.119 In vaccine development, nanoparticle-based influenza vaccines induce stronger and broader cross-protective immunity than traditional formulations.120,121 Likewise, respiratory syncytial virus (RSV) nanovaccines based on different scaffolds consistently enhance neutralizing antibody responses and reduce viral loads,122 while chitosan-coated liposomal systems improve mucosal retention and therapeutic outcomes.123 In addition to organic nanocarriers, inorganic nanoparticles such as silver nanoparticles (AgNPs) have demonstrated immune-modulatory antiviral effects. Intratracheal AgNP administration prior to viral exposure enhances innate immune recruitment and reduces viral burden through macrophage–NK cell crosstalk.124 Furthermore, hybrid nanocarriers combining inorganic and organic components enable high drug loading and targeted delivery for viral replication inhibition.125 These findings collectively highlight the versatility of nanotechnology in integrating antiviral, immunomodulatory, and vaccine functions within a single platform. In addition, nanotechnology-based drug delivery systems provide a versatile platform for improving the treatment of viral respiratory infections by enhancing antiviral drug delivery, modulating host immune responses, and enabling vaccine development. These systems overcome key limitations of conventional therapies, including poor bioavailability, systemic toxicity, and emerging drug resistance. Importantly, multifunctional nanoplatforms, as exemplified in Figure 4, integrate antiviral and anti-inflammatory effects while improving lung targeting and therapeutic efficiency. Overall, current evidence supports a shift toward integrated nanomedicine strategies that simultaneously target viral replication and host immune regulation. Fungal Pneumonia Respiratory fungal infections represent a persistent global health burden, responsible for approximately 1.5 million deaths annually.126 Epidemiologically, the spectrum of pathogens has remained relatively stable but clinically challenging, with Aspergillus, Candida, Cryptococcus, Pneumocystis jirovecii, and Mucormycetes continuing to dominate invasive pulmonary infections.127 Despite the availability of systemic antifungals—including azoles, echinocandins, and amphotericin B—their clinical utility is frequently constrained by toxicity, suboptimal lung exposure, and the need for prolonged administration.128,129 Among these limitations, nephrotoxicity and poor pulmonary targeting of amphotericin B remain particularly critical barriers, reinforcing the need for delivery systems that can simultaneously improve safety and local drug bioavailability.130 From a translational perspective, NDDS provides a key opportunity to decouple antifungal efficacy from systemic toxicity by improving lung-specific accumulation and controlled release. Liposomal amphotericin B already represents a clinically validated example of this principle, where lipid encapsulation reduces renal toxicity while enhancing passive lung targeting.130 This clinical success essentially establishes nanocarrier-mediated antifungal delivery as a viable therapeutic paradigm rather than a purely experimental strategy. Building on this foundation, inhalable polymeric and lipid-based nanosystems have been developed to further optimize pulmonary deposition and residence time. For instance, chitosan-based itraconazole nanoparticles achieved appropriate aerodynamic size (~2–3 μm) for deep lung delivery, improving inhalation efficiency.131 In a similar direction, lipid–polymer hybrid nanoparticles of voriconazole (LPH NPs) demonstrated significantly enhanced lung retention and sustained drug exposure. As illustrated in Figure 6,132 the DPPC/chitosan coating strategy improves nanoparticle stability and facilitates clathrin-mediated cellular uptake in alveolar epithelial cells, which is consistent with the observed higher intracellular accumulation. Correspondingly, in vivo pharmacokinetic data show markedly increased pulmonary AUC and prolonged drug retention, which translated into reduced fungal burden and improved histopathological outcomes in pulmonary aspergillosis models. These findings collectively highlight that rational surface engineering, rather than drug selection alone, is a decisive factor in improving antifungal pulmonary delivery. Beyond conventional carrier systems, emerging stimuli-responsive and immune-interactive nanoplatforms are reshaping antifungal strategy design. Near-infrared (NIR)-responsive conjugated polymer nanoparticles, for example, enable on-demand immune activation, enhancing macrophage-mediated fungal clearance while reducing tissue damage.133 In parallel, lipid-based nanostructures such as solid lipid nanoparticles have been shown to improve drug stability and local anti-inflammatory effects in fungal pneumonia models.134 These approaches collectively suggest a shift from passive drug delivery toward “functionally active nanomedicine,” where carriers themselves participate in host–pathogen interaction modulation. DPPC-coated chitosan hybrid nanoparticles for pulmonary voriconazole delivery. (A) Preparation of dipalmitoyl phosphatidylcholine (DPPC) coated chitosan hybrid nanoparticles by electrostatic interaction method. (B) Pharmacokinetic profiles of voriconazole (VRC) and lipid-polymer hybrid nanoparticles (LPH NPs) at different time-points in Lungs and Plasma, following nebulization for 20 min to Balb/c mice through inhouse nose-only inhalation chamber. (C) Time-dependent cellular uptake of lipid-polymer hybrid nanoparticles in A549 3 cells and Calu 3 cells. (D) Fluorescence microscopic images of cellular uptake of Rhodamine 123 loaded lipid-polymer hybrid nanoparticles: (i) A549 control cells, (ii) A549 treated cells, (iii) Calu 3 control cells, and (iv) Calu 3 treated cells. (E) Histopathological changes in lungs of Balb/c mice after receiving twice daily nebulisation of control, normal saline, VRC and LPH NP dispersion for a period of 21 days. AS alveolar sac. Reproduced/adapted under CC BY 4.0. More advanced biomaterial systems further reinforce this trend. Nanohydrogels designed for voriconazole delivery demonstrate effective mucus penetration and sustained release, particularly relevant in cystic fibrosis-associated fungal infections, where mucus barriers severely limit drug access.135 Similarly, green-synthesized gold nanoparticles exhibit intrinsic antifungal activity through hyphal disruption and immunomodulation, indicating that inorganic nanomaterials may serve dual therapeutic roles.136 However, such systems must still be carefully evaluated for long-term biocompatibility and clinical scalability. To further improve pulmonary targeting precision, surface-modified lipid nanoparticles (DPPC/DMPG) and inhalable dry powder systems have been engineered to optimize lung deposition and retention. These formulations significantly reduce fungal burden in vivo, as demonstrated by decreased galactomannan levels and improved histological recovery.137–139 Importantly, these delivery strategies are not merely formulation variations but represent systematic attempts to align particle behavior with pulmonary physiology. A particularly notable translational advance is the development of oral lipid nanocrystal amphotericin B, which achieved antifungal efficacy comparable to intravenous liposomal formulations in mucormycosis models, while significantly improving survival outcomes.140 In parallel, targeted ethosomal systems functionalized with CFW-PEc enhance amphotericin B delivery to Cryptococcus neoformans, achieving markedly reduced lung fungal burden in vivo.141 These studies collectively indicate that nanodelivery is expanding antifungal therapy beyond inhalation toward systemic-but-targeted administration routes. Overall, current nanotechnology-based antifungal systems consistently demonstrate improved pulmonary drug delivery, enhanced local retention, and reduced systemic toxicity compared with conventional formulations. However, most existing studies remain at the preclinical stage and are characterized by heterogeneous designs, limiting direct clinical comparability. A key emerging insight is that therapeutic efficacy is increasingly governed by rational engineering of lung-targeting behavior and host–pathogen microenvironment interaction rather than drug modification alone. Future research should therefore prioritize clinically translatable, physiologically adaptive nanoplatforms that integrate delivery efficiency with immune-modulatory functionality. Current Challenges and Future Directions NDDS have demonstrated clear advantages in enhancing pulmonary drug delivery and therapeutic precision in lower respiratory infections. However, despite promising preclinical outcomes, their clinical translation remains constrained by interrelated challenges spanning safety, delivery efficiency, and manufacturability. A unified biosafety evaluation framework is particularly important for nanocarriers intended for repeated pulmonary administration. Such assessment should include particle size distribution, surface charge, morphology, drug-loading reproducibility, aerosol performance, cytotoxicity in airway epithelial cells and macrophages, oxidative stress, inflammatory cytokine induction, hemocompatibility where relevant, immunogenicity, biodistribution, biodegradation, long-term pulmonary retention, and repeated-dose toxicity. From a safety perspective, long-term pulmonary retention and material-associated toxicity remain primary concerns. Inorganic nanoparticles, for example, may persist in lung tissue and trigger chronic inflammatory responses, including macrophage activation and fibrosis.142 Even for biodegradable systems such as PLGA, degradation behavior is highly context-dependent, with variations in local pH, enzymatic activity, and particle structure leading to unpredictable drug release kinetics.143 In addition, repeated administration of surface-modified nanoparticles—particularly PEGylated systems—may induce immune recognition and accelerated clearance, thereby reducing therapeutic retention and efficacy.135 These observations collectively suggest that biocompatibility alone is insufficient; predictable in vivo behavior must become a central design criterion for next-generation NDDS. Beyond safety, delivery efficiency within the pulmonary microenvironment remains a critical bottleneck. The respiratory tract presents multiple biological barriers, including mucus hypersecretion, altered rheology, and impaired mucociliary clearance, particularly in chronic conditions such as cystic fibrosis. These factors can significantly hinder nanoparticle diffusion and reduce effective drug deposition.144 Moreover, particle size distribution remains a key determinant of therapeutic success: larger particles fail to reach the alveolar region, whereas smaller particles are prone to rapid clearance, underscoring the need for precise aerodynamic control. Taken together, these challenges highlight that successful pulmonary delivery is governed not only by nanoparticle composition but also by its dynamic interaction with airway physiology. From a translational standpoint, manufacturing and scalability issues further limit clinical adoption. Achieving reproducible large-scale production of nanoparticles with consistent size, drug loading, and stability remains technically demanding.145 In addition, the high cost associated with complex nanofabrication processes poses economic barriers compared with conventional formulations. These factors emphasize that clinical translation requires not only biological efficacy but also industrial feasibility and cost-effectiveness. Looking forward, future development of NDDS is likely to shift from passive delivery platforms toward more adaptive and functionally integrated systems. Stimuli-responsive nanoparticles capable of releasing drugs in response to infection-associated microenvironmental cues offer improved targeting precision and reduced off-target effects. At the same time, theranostic nanoplatforms integrating diagnostic and therapeutic functions may enable real-time monitoring of disease progression and treatment response, supporting more personalized therapeutic strategies. Equally important is the optimization of inhalable delivery technologies. Advances in aerosol engineering and nebulization systems are essential to ensure efficient deep lung deposition and reproducible dosing. In parallel, standardized evaluation frameworks for pulmonary safety, immunogenicity, pharmacokinetics, and manufacturing consistency will be critical for regulatory approval and clinical translation. Overall, the major barriers to NDDS translation are not limited to individual material properties but arise from the complex interplay between nanoparticle design, pulmonary biology, and manufacturing constraints. Future progress will depend on integrating these dimensions into a unified design framework rather than addressing them in isolation. In particular, improving the predictability of in vivo behavior and aligning nanoparticle function with disease-specific microenvironments will be essential. Such advances are expected to drive the transition of NDDS from experimental systems to clinically viable therapeutic platforms. Conclusion NDDS are reshaping therapeutic strategies for lower respiratory infections by enabling targeted, sustained, and multifunctional drug delivery within the pulmonary microenvironment. Across bacterial pneumonia, tuberculosis, viral infections, and fungal pneumonia, the studies reviewed herein reveal several cross-cutting principles. First, effective pulmonary nanotherapy depends on aligning carrier properties with disease-specific biological barriers. Biofilm penetration and antibacterial synergy are particularly important in bacterial pneumonia; macrophage targeting and prolonged therapeutic exposure are central to tuberculosis treatment; efficient intracellular antiviral delivery and regulation of excessive host inflammation are critical in viral infections; and sustained local antifungal exposure is essential for fungal pneumonia. Second, therapeutic performance is determined not only by drug-loading capacity, but also by surface engineering, interactions with airway mucus, intracellular delivery efficiency, and the ability to modulate host–pathogen microenvironments. Importantly, the reported improvements in lung deposition, local retention, therapeutic efficacy, and toxicity reduction remain largely formulation- and model-dependent preclinical observations. Their translational value will depend on whether these benefits can be reproduced under standardized pharmacokinetic, safety, efficacy, and manufacturing conditions. Direct quantitative comparisons across studies remain difficult because of substantial heterogeneity in nanocarrier composition, therapeutic agents, administration routes, infection models, dosing regimens, and outcome measures. Therefore, future investigations should prioritize standardized evaluation frameworks, clinically relevant comparative studies, long-term pulmonary safety assessment, and robust characterization of biodistribution and clearance. The field is consequently moving beyond proof-of-concept formulations toward adaptive and functionally integrated platforms that combine controlled release, disease-site targeting, immunomodulatory activity, and scalable production. Future progress will require closer integration of nanomaterial design, pulmonary physiology, pathogen biology, aerosol engineering, and regulatory evaluation. With continued interdisciplinary refinement and rigorous clinical validation, NDDS may become an important component of next-generation precision anti-infective therapy for lower respiratory infections. AI-Assisted Content Disclosure ChatGPT version 5.6 was used to assist in research data visualization for Figure 1. Author Contributions All authors made a significant contribution to the work reported, whether that is in the conception, study design, execution, acquisition of data, analysis and interpretation, or in all these areas; took part in drafting, revising or critically reviewing the article; gave final approval of the version to be published; have agreed on the journal to which the article has been submitted; and agree to be accountable for all aspects of the work. The originality and accuracy of all figure content has been confirmed by the authors. Authors take full responsibility for the integrity of the whole content, including the accuracy of references. Authors have checked terms of use for the specific AI tool used and therefore confirm suitability for publication. Authors have the right to publish the generated images and have obtained permissions where required. Disclosure No conflicts of interest. References